Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Cancer Res. 2020 Oct 6;80(23):5344–5354. doi: 10.1158/0008-5472.CAN-19-0677

Fig. 3. NSG mice in vivo studies: tumor growth in the presence of XPO1i and MEL.

Fig. 3.

NSG mice were challenged with human U266 and MEL-resistant U266-LR6 MM cells (subcutaneous flank injection) and treated with single agent SEL or ELT ± MEL. Mice were assayed for (A) U266 tumor growth, (B) MEL-resistant U266-LR6 tumor growth, (C) U266 tumor survival, and (D) MEL-resistant U266-LR6 tumor survival. Mice were euthanized when tumor volumes reached 2000 mm3. No toxicity (defined as weight loss > 10%) was observed.